FIELD: chemistry.
SUBSTANCE: invention relates to laboratory diagnostics and can be used to determine fibrinogen and evaluate its functionality. Method for determining fibrinogen (FG) during recalcification of citrate plasma and its functionality involves activating a coagulation contact path in polystyrene 96-well flat-bottomed immunoassay plates by mixing citrated blood plasma with calcium chloride followed by photometric recording of coagulation, wherein to intensify fibrinogen coagulation, osmolarity is reduced in the test sample by adding 50 mcl of distilled water to 150 mcl of the test system, 50 mcl of VBS buffer is added in the control sample instead of water, coagulation reaction is started by addition of 50 mcl 25 mM CaCl2 into sample, thoroughly mixed, optical density of samples is measured, then incubated for 120 min at 37 °C, determination of plasma coagulation is carried out photometrically by turbidity change of samples at wave length of 450 nm with measurement intervals of 0 and 120 minutes, in initial plasma content of FG is determined by Klaus method, calculating an individual coefficient for transfer of changes in optical density in the sample during coagulation as a relation of FG by Klaus to change in the optical density of the sample (ΔA450), average coefficient and fibrinogen content are calculated by formula: FG (g/l) = ΔA450 × 4.9, where: ΔA450 is change of optical density of the sample during plasma coagulation; 4.9 is the average value of the coefficient for transforming the optical density of the sample in plasma coagulation in g/l of fibrinogen; the fibrinogen dysfunctions are determined as the difference between the amounts of fibrinogen determined by the given method and method.
EFFECT: invention provides a simple, informative and specific test for determining fibrinogen and its functionality and enables wide screening and detecting people prone to thrombosis.
1 cl, 4 tbl, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2703541C1 |
METHOD FOR OXIDATION-MODIFIED FIBRINOGEN | 2020 |
|
RU2732385C1 |
METHOD FOR DETERMINING FIBRINOGEN AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2712643C1 |
METHOD FOR DETERMINING ACTIVITY OF MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASES IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2739113C1 |
DETERMINING OF CIRCULATING THROMBIN IN COMPLEMENT ACTIVATION TEST | 2019 |
|
RU2709341C1 |
METHOD OF DETERMINING THROMBIN COMPLEMENTARITY SYSTEM ACTIVATION PATHWAY | 2019 |
|
RU2717946C1 |
SCREENING-TEST OF DETERMINING COAGULATION CONTACT WAY (STOKPK) | 2017 |
|
RU2660706C1 |
DETERMINING THE ACTIVITY OF THE CLASSICAL PATHWAY OF THE COMPLEMENT SYSTEM IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2707568C1 |
METHOD FOR DETERMINING BLOOD PLASMA COAGULATION INDICATORS - THROMBIN ACTIVITY, PLASMA RECALCIFICATION TIME AND PLASMA TOLERANCE TO HEPARIN | 2020 |
|
RU2786591C2 |
DETERMINING HUMAN ERYTHROCYTE SENSITIVITY TO LYSIS WITH COMPLEMENT SYSTEM ACTIVATION ON THROMBIN PATHWAY | 2019 |
|
RU2696981C1 |
Authors
Dates
2020-09-16—Published
2020-04-27—Filed